is Novo Nordisk previous its ‘peak uncertainty’?

Contents

Analysts’ views Boardroom meltdown Earnings releases this week:

At one level, it was Europe’s most beneficial firm.

Now, as Danish pharmaceutical group Novo Nordisk prepares to publish its third-quarter earnings on Wednesday, the image seems to be very totally different.

Jonathan Raa | Nurphoto | Getty Photos

CNBC’s Charlotte Reed will journey to Copenhagen to talk with the corporate’s new CEO Mark Doustdar, a 30-year veteran of the corporate, who has been within the high job since August.

It is not been a simple journey to date, with the group asserting a pointy decline in gross sales, strain on revenue, a spherical of jobs cuts and continued competitors from U.S. rivals with regards to the blockbuster weight problems drug market.

Analysts’ views

Regardless of this, Berenberg is constructive on the inventory, saying Novo has hit “peak uncertainty.”

“Novo’s superior development profile and best-in-class R&D returns warrants a better valuation premium to its friends,” the financial institution added.

Different analysts are much less forgiving.

Jefferies lately reduce the inventory’s score to underperform, citing aggressive strain within the U.S. and pricing issues. In the meantime, UBS analysts are involved Novo’s 8 billion Danish krone ($1.23 billion) one-off value associated to its restructuring has not been totally mirrored on the underside line, whereas including that buyers are persevering with to query the group’s lack of shopper expertise within the American market.

On Oct. 17, U.S. President Donald Trump advised a press convention that the value of Novo’s blockbuster weight-loss drug Ozempic could be “a lot decrease” as a part of the administration’s negotiations over pricing with the corporate.

The share worth has been underneath strain for the reason that begin of the 12 months.

Powerful 12 months for Novo Nordisk shares